A Propensity Score Matched Analysis of Superparamagnetic Iron Oxide versus Radioisotope Sentinel Node Biopsy in Breast Cancer Patients after Neoadjuvant Chemotherapy.
SPIO
breast cancer
neoadjuvant chemotherapy
radioisotope
sentinel lymph node biopsy
superparamagnetic iron oxide
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Jan 2022
28 Jan 2022
Historique:
received:
10
01
2022
revised:
26
01
2022
accepted:
27
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
The standard method for nodal staging in breast cancer (BC) patients after neoadjuvant chemotherapy (NAC) is sentinel lymph node biopsy (SLNB) with a radioisotope (RI) injection. However, SLNB after NAC results in high false-negative rates (FNR), and the RI method is restricted by nuclear medicine unit dependency. These limitations resulted in the development of the superparamagnetic iron oxide (SPIO) method, reducing FNR and presenting a comparable detection rate. This bi-institutional cohort comparison study aimed to assess the efficacy of SPIO and radioisotope SNLB in BC patients after NAC using Propensity Score Matching (PSM) analysis. The study group comprised 508 patients who underwent SLNB after NAC for ycT1-4N0M0 BC between 2013 and 2021 in two high volume centers. Data were retrieved from prospectively conducted databases. In the SPIO group, the median of retrieved sentinel lymph nodes (SLNs) was significantly higher than in the RI group (3 vs. 2;
Identifiants
pubmed: 35158944
pii: cancers14030676
doi: 10.3390/cancers14030676
pmc: PMC8833727
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2005 Apr 20;23(12):2694-702
pubmed: 15837984
J Surg Oncol. 2016 Apr;113(5):501-7
pubmed: 26754343
Ann Surg Oncol. 2019 Aug;26(8):2409-2416
pubmed: 31065958
Medicine (Baltimore). 2020 Dec 4;99(49):e23538
pubmed: 33285770
Eur J Surg Oncol. 2015 Jan;41(1):46-51
pubmed: 25466980
Lancet Oncol. 2013 Jun;14(7):609-18
pubmed: 23683750
Sci Technol Adv Mater. 2015 Apr 28;16(2):023501
pubmed: 27877761
Future Oncol. 2018 Jun;14(15):1423-1426
pubmed: 29714081
J Natl Compr Canc Netw. 2020 Apr;18(4):452-478
pubmed: 32259783
Ann Surg Oncol. 2014 Apr;21(4):1237-45
pubmed: 24322530
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
J Clin Med. 2021 Jul 16;10(14):
pubmed: 34300315
JAMA. 2013 Oct 9;310(14):1455-61
pubmed: 24101169
Cancers (Basel). 2021 Jun 11;13(12):
pubmed: 34208090
Lancet Oncol. 2014 Jul;15(8):e351-62
pubmed: 24988938
Nat Rev Clin Oncol. 2015 Jun;12(6):335-43
pubmed: 25850554
Breast. 2014 Apr;23(2):175-9
pubmed: 24484967
Ann Ital Chir. 2020;91:465-468
pubmed: 32312945
Ann Surg Oncol. 2021 Jul;28(7):3738-3748
pubmed: 33156466
BJS Open. 2019 Mar 25;3(4):445-452
pubmed: 31388636
Breast Care (Basel). 2019 Apr;14(2):103-110
pubmed: 31798382
Ann Surg Oncol. 2019 May;26(5):1247-1253
pubmed: 30830536
BMC Med Imaging. 2020 May 27;20(1):58
pubmed: 32460834
J Surg Oncol. 2019 Dec;120(8):1391-1396
pubmed: 31667855
Cancers (Basel). 2021 Oct 08;13(19):
pubmed: 34638516
Curr Breast Cancer Rep. 2014 Mar;6(1):10-16
pubmed: 24683440
Ann Surg Oncol. 2010 Jul;17(7):1854-61
pubmed: 20300966
Lancet Oncol. 2016 Oct;17(10):e430-e441
pubmed: 27733269
World J Surg Oncol. 2021 Mar 29;19(1):93
pubmed: 33781279
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Cancers (Basel). 2021 Mar 29;13(7):
pubmed: 33805367
Ann Surg Oncol. 2019 Oct;26(11):3510-3516
pubmed: 31297674
J Clin Oncol. 2009 Feb 10;27(5):726-32
pubmed: 19114697
Eur J Cancer Care (Engl). 2017 Jul;26(4):
pubmed: 26365441
Crit Rev Oncol Hematol. 2018 Mar;123:83-94
pubmed: 29482783
Front Oncol. 2020 Jul 17;10:1061
pubmed: 32766138